4RY.F AKESO INC. O.N.

Healthcare Biotechnology Frankfurt Exchange
10.10 EUR
Close of Nov 11, 2026
8.68 16.41
Market cap
EUR 9.50B
P/E
-
P/B
8.30x
ROE
-12.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4RY.F undervalued?

Graham number

The Graham number of AKESO INC. O.N. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AKESO INC. O.N. fundamental analysis

No fundamental analysis for AKESO INC. O.N. yet.

AKESO INC. O.N. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AKESO INC. O.N.

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also deve…

Full company profile